Study of HBV- X gene mutation among patients with HBV- related chronic hepatitis, liver cirrhosis, and primary liver cancer

Abstract

Objective To study the relationship between hepatocarcinogenesis and the mutation in X gene among patients with chronic hepatitis B virus ( HBV) infection, such as chronic hepatitis B ( CHB) , liver cirrhosis ( LC) and primary liver cancer ( PLC) . Methods The serum samples from 89 patients with chronic HBV infection who visited the Second Affiliated Hospital of Chongqing Medical University from2011 to 2013 were collected. PCR was used to amplify the X gene of HBV DNA extracted from the serum samples. After sequencing, the HBV- X genome was compared with those reported in GenBank to find the variable sites and variant forms. Chi- square and one- way ANOVA were used for the statistical analysis afterwards, whereas genotypes were determined by the genotyping tool of the National Center for Biotechnology Information. Results All patients were genotype B or C. Among HBeAg- positive patients, 46. 2% were genotype B, and53. 8% were genotype C; among HBeAg- negative patients, 81. 2% were genotype B, and 18. 8% were genotype C ( P = 0. 001) . PLC patients had a significantly higher risk of mutation in the basic core promoter ( BCP) region than the CHB and LC groups ( 69. 2% vs 34. 4%and 61. 3%, P < 0. 05) ; in addition, an evident T- base deficiency was observed at nt1821 site ( 88. 5% vs 53. 1% and 71%, P =0. 014) . Among CHB and LC patients, those with genotype C had a significantly higher risk of BCP double mutation than those with genotype B ( 61. 5% vs 15. 8%, P = 0. 007; 83. 3% vs 47. 4%, P = 0. 045) . The incidence of BCP double mutation was significantly higher in the low- viral load group ( ≤106copies /ml) than in the high- viral load group ( > 106copies /ml) ( 81. 3% vs 47. 9%, P = 0. 015) .Conclusion The BCP double mutation and T- base deficiency at nt1821 site may play important roles in the development of PLC.
- hepatitis B, chronic,
- liver cirrhosis,
- carcinoma, hepatocellular,
- hepatitis B virus,
- point mutation

FullText(HTML)

References(32)

References

[1]WU ZD, WU ZH.Surgery[M].6th ed.Beijing:People's Medical Publishing House, 2002:518-524. (in Chinese) 吴在德, 吴肇汉.外科学[M].6版.北京:人民卫生出版社, 2002:518-524.

[2]FARAZI PA, DEPINHO RA.Hepatocellular carcinoma pathogenesis:from genes to environment[J].Nat Rev Cancer, 2006, 6 (9) :674-687.

[3] GANEM D, PRINCE AM.Hepatitis B virus infection-natural history and clinical consequences[J].N Engl J Med, 2004, 350 (11) :1118-1129.

[4]BLOCK TM, MEHTA AS, FIMMEL CJ, et al.Molecular viral oncology of hepatocellular carcinoma[J].Oncogene, 2003, 22 (33) :5093-5107.

[5]MA L, ZHANG W, XU GZ, et al.Expressions of HBx and CEACAM1 in HBV related hepatocellular carcinoma and their significances[J].J Jilin Univ:Med Edit, 2012, 38 (4) :770-774. (in Chinese) 马莉, 张蔚, 许刚柱, 等.乙型肝炎病毒相关性肝癌患者癌组织中HBx和CEACAM1的表达及其意义[J].吉林大学学报:医学版, 2012, 38 (4) :770-774.

[6]CHEMIN I, ZOULIM F.Hepatitis B virus induced hepatocellular carcinoma[J].Cancer Lett, 2009, 286 (1) :52-59.

[7]KOIKE K.Hepatitis B virus X gene is implicated in liver carcinogenesis[J].Cancer Lett, 2009, 286 (1) :60-68.

[8]KIDD-LJUNGGREN K, MIYAKAWA Y, KIDD AH.Genetic variability in hepatitis B viruses[J].J Gen Virol, 2002, 83 (Pt6) :1267-1280.

[9]KIDD-LJUNGGREN K, MYHRE E, BLACKBERG J.Clinical and serological variation between patients infected with different Hepatitis B virus genotypes[J].J Clin Microbiol, 2004, 42 (12) :5837-5841.

[10]SONG BC, CUI XJ, KIM HU, et al.Sequential accumulation of the basal core promoter and the precore mutations in the progression of hepatitis B virus-related chronic liver disease[J].Intervirology, 2006, 49 (5) :266-273.

[11]BAUMERT TF, MARRONE A, VERGALLA J, et al.Naturally occurring mutations define a novel function of the hepatitis B virus core promoter in core protein expression[J].Virology, 1998, 72 (8) :6785-6795.

[12]SCAGLIONI PP, MELEGARI M, WANDS JR.Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame[J].Virology, 1997, 233 (2) :374-381.

[13]DATTA S, BANERJEE A, CHANDRA PK, et al.Analysis of hepatitis B virus X gene phylogeny, genetic variability and its impact on pathogenesis:implications in Eastern Indian HBV carriers[J].Virology, 2008, 382 (2) :190-198.

[14]TANAKA Y, MIZOKAMI M.Genetic diversity of hepatitis B virus as an important factor associated with differences in clinical outcomes[J].Infect Dis, 2007, 195 (1) :1-4.

[15]SHINKAI N, TANAKA Y, ITO K, et al.Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2[J].Clin Microbiol, 2007, 45 (10) :3191-3197.

[16] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.

[17]Ministry of Health of the People's Republic of Clina.Diagnosis, management, and treatment of hepatocellular carcinoma (V2011) [J].J Clin Hepatol, 2011, 27 (11) :1141-1159. (in Chinese) 中华人民共和国卫生部.原发性肝癌诊疗规范 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1159.

[18]KUANG SY, JACKSON PE, WANG JB, et al.Specific mutations of hepatitis B virus in plasma predict liver cancer development[J].PNAS, 2004, 101 (10) :3575-3580.

[19]LIZZANO RA, YANG B, CLIPPINGER AJ, et al.The C-terminal region of the hepatitis B virus X protein is essential for its stability and function[J].Virus Res, 2011, 151 (1) :231-239.

[20]LIU XH, LIN J, ZHANG SH, et al.COOH-terminal deletion of HBx gene is a frequent event in HBV-associated hepatocellular carcinoma[J].Gastroenterol, 2008, 14 (9) :1346-1352.

[21] MA NF, LAU SH, HU L, et al.COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis[J].Clin Cancer Res, 2008, 14 (16) :5061-5068.

[22]WANG Y, CHEN P, WU X, et al.A new enhancer element, ENII, identified in the X gene of hepatitis B virus[J].Virology, 1990, 64 (8) :3977-3981.

[23]WU X, ZHU L, LI ZP, et al.Functional organization of enhancer (ENII) of hepatitis B virus[J].Virology, 1992, 191 (1) :490-491.

[24]LI M, XIE Y, WU X, et al.HNF3 binds and activates the second enhancer, ENII, of hepatitis B virus[J].Virology, 1995, 214 (2) :371-378.

[25]FAN WM, SHI BY, WEI HS, et al.Comparison of hepatitis B X gene mutation between patients with hepatocellular carcinoma and patients with chronic hepatitis B[J].Virus Genes, 2011, 42 (2) :162-170.

[26]CHEN ST, La PORTE P, YEE JK.Mutational analysis of hepatitis B virus enhancer 2[J].Virology, 1993, 196 (2) :652-659.

[27]PANG A, YUEN MF, YUAN HJ, et al.Real-time quantification of hepatitis B virus core-promoter and pre-core mutants during hepatitis e antigen seroconversion[J].J Hepatol, 2004, 40 (6) :1008-1017.

[28]KAO JH, CHEN PJ, LAI MY, et al.Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers[J].Gastroenterology, 2003, 124 (2) :327-334.

[29]FANG ZL, YANG J, GE X, et al.Core promoter mutations (A (1762) T and G (1764) A) and viral genotype in chronic hepatitis B and hepatocellular carcinoma in Guangxi, China[J].Virology, 2002, 68 (1) :33-34.

[30]GUO X, JIN Y, QIAN G, et al.Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China[J].J Hepatol, 2008, 49 (5) :718-725.

[31]LI WH, CHEN GY, YU XW, et al.Accumulation of the mutations in basal core promoter of hepatitis B virus subgenotype C1 increase the risk of hepatocellular carcinoma in Southern China[J].Int J Clin Exp Pathol, 2013, 6 (6) :1076-1085.

[32]CHEN YM, YU DJ, ZHANG WY, et al.HBV subgenotype C2 infection, A1762T/G1764A mutations may contribute to hepatocellular carcinoma with cirrhosis in southeast China[J].Iranian J Public Health, 2012, 41 (11) :10-18.

Relative Articles

[1]	Radiology of Infection Sub-branch, Radiology Branch, Chinese Medical Association, Committee on Radiology of Infection, Radiology Branch, Chinese Medical Doctor Association, Radiology Committee on Infectious and Inflammatory Disease, Chinese Research Hospital Association, Radiology of Infection Branch, Working and Treating Committee of HIV/AIDS and STD Association, Radiology of Infectious Disease Management Sub-branch, Infectious Disease Management Branch, Hospital Management Association in China, Beijing Imaging Diagnosis and Treatment Technology Innovation Alliance. Consensus on imaging techniques and diagnostic criteria for hepatitis B virus related early hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(4): 787-791. doi: 10.3969/j.issn.1001-5256.2021.04.013
[2]	Xie XiaoHong, Yang DongLiang, Liu Jia. Role and mechanism of action of intrahepatic intrinsic antigen-presenting cells in regulating anti-hepatitis B virus immune response[J]. Journal of Clinical Hepatology, 2020, 36(5): 965-970. doi: 10.3969/j.issn.1001-5256.2020.05.002
[3]	Huang KuiYuan, Liu ZiYing, Zhang XiaoYong. Hepatitis B cured by the activation of intrahepatic innate immunity:Research advances and new strategies[J]. Journal of Clinical Hepatology, 2020, 36(5): 971-976. doi: 10.3969/j.issn.1001-5256.2020.05.003
[4]	Yu Zhe, Yang YongPing. Concurrent hepatitis D virus infection increases risk of hepatocellular carcinoma in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2020, 36(4): 944-947. doi: 10.3969/j.issn.1001-5256.2020.04.053
[5]	Yan YongCong, Wen Kai, Mao Kai, Xiao ZhiYu, Wang Jie. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(10): 2167-2172. doi: 10.3969/j.issn.1001-5256.2020.10.002
[6]	Ren DanDan, Liu Na, Zhou LuLu, Zhang Nan, Li ChunXia, Dong Bing, Xu GuangHua. Risk factors for hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1634-1638. doi: 10.3969/j.issn.1001-5256.2020.07.041
[7]	Lin Jian, Fang XueQing, Song YouLiang. A case of recurrent liver dysfunction caused by NBAS gene mutation[J]. Journal of Clinical Hepatology, 2020, 36(9): 2069-2071. doi: 10.3969/j.issn.1001-5256.2020.09.034
[8]	Sun Jing, Zhu Lin, Chi Xin, Wang YiXuan, Xing HuiChun. Effect of entecavir antiviral therapy alone or combined with interferon on the risk of hepatocellular carcinoma in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2020, 36(9): 1975-1979. doi: 10.3969/j.issn.1001-5256.2020.09.013
[9]	Wu ShanShan, Kong YuanYuan. Methodology of establishing predictive models for clinical endpoints in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2020, 36(9): 1923-1927. doi: 10.3969/j.issn.1001-5256.2020.09.002
[10]	Liu XiaoJu, Zhang Zheng. Functional cure of chronic hepatitis B from the perspective of specific immune cells for hepatitis B virus[J]. Journal of Clinical Hepatology, 2020, 36(5): 977-979. doi: 10.3969/j.issn.1001-5256.2020.05.004
[11]	Shi Ke, Zhang Qun, Li YuXin, Wang XianBo. Research advances in the risk prediction models for chronic hepatitis B-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(10): 2315-2319. doi: 10.3969/j.issn.1001-5256.2020.10.034
[12]	He YaJing, Zhang ZhiMing, He WeiMeng, Hou JinLin. Epidemiological characteristics and prognosis of hepatocellular carcinoma: A single-center observational real-world cohort study of 1302 cases[J]. Journal of Clinical Hepatology, 2019, 35(5): 1002-1007. doi: 10.3969/j.issn.1001-5256.2019.05.014
[13]	Xiong Fang, Ma YanPin, Bao XuLi, Lu: Jun. Change in the level of T-cell receptor rearrangement excision circles after antiviral therapy in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2019, 35(11): 2449-2452. doi: 10.3969/j.issn.1001-5256.2019.11.012
[14]	Fan MengJie, Zeng Zheng. Influence of dual positivity of HBsAg and anti-HBs on the development of hepatocellular carcinoma in patients with chronic hepatitis B: A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(8): 1723-1727. doi: 10.3969/j.issn.1001-5256.2019.08.015
[15]	An BaiQuan, Xin YongNing, Lu LinLin, Xuan ShiYing. Effect of PNPLA3 I148M mutation on expression of TGF- β1 in rat hepatic stellate cells[J]. Journal of Clinical Hepatology, 2016, 32(4): 769-771. doi: 10.3969/j.issn.1001-5256.2016.04.035
[16]	Jin WenWen, Xin YongNing, Dong QuanJiang, Zhao ShouFeng, Yu XinJuan, Jiang Man, Xu Jing, Xuan ShiYing. The preliminary study on the relationship between hepatitis B virus BCP gene mutations and HBV-related primary hepatocellular carcinoma in Qingdao[J]. Journal of Clinical Hepatology, 2012, 28(2): 130-134.
[17]	Luo LiSha, Zhang JiWan, Zhou JianLi, Kang Ning, He PengFei, Long Li, Zhang XiaoFang, Zhao ZhiYong, Wang HaiBin. Changes on the spots mutation of complement receptor type 1 and on erythrocytes immune adhesion function in HBeAg positive hepatitis patients[J]. Journal of Clinical Hepatology, 2010, 26(6): 635-637.
[19]	Hou YuanPei, Liu ChengYong, Gao YuJin. Affection of the mutations and genotypes of hepatitis B virus precore and basic core promoter on HBeAg expression[J]. Journal of Clinical Hepatology, 2007, 23(4): 251-253.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2562) PDF downloads(541)

Study of HBV- X gene mutation among patients with HBV- related chronic hepatitis, liver cirrhosis, and primary liver cancer

DOI: 10.3969/j.issn.1001-5256.2014.06.013

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Study of HBV- X gene mutation among patients with HBV- related chronic hepatitis, liver cirrhosis, and primary liver cancer

DOI: 10.3969/j.issn.1001-5256.2014.06.013

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content